Principal Financial Group
SNDX icon

Principal Financial Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Principal Financial Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,167
Closed -$291K – 2395
2024
Q2 		$291K Sell
14,167
-4,662
-25% -$97.6K ﹤0.01% 2063
2024
Q1 		$448K Sell
18,829
-36,365
-66% -$811K ﹤0.01% 2011
2023
Q4 		$1.19M Buy
55,194
+12,074
+28% +$186K ﹤0.01% 1820
2023
Q3 		$626K Buy
43,120
+9,371
+28% +$177K ﹤0.01% 1911
2023
Q2 		$706K Buy
33,749
+6,014
+22% +$125K ﹤0.01% 1890
2023
Q1 		$586K Buy
27,735
+417
+2% +$10.4K ﹤0.01% 1938
2022
Q4 		$695K Buy
27,318
+15,280
+127% +$356K ﹤0.01% 1910
2022
Q3 		$289K Buy
+12,038
New +$270K ﹤0.01% 2092
2021
Q3 		– Sell
-10,893
Closed -$187K – 2618
2021
Q2 		$187K Buy
+10,893
New +$200K ﹤0.01% 2484

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Financial Group's SNDX Position: Q3 2024 in Review

Principal Financial Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 14,167 shares — an estimated $291K sold.

Principal Financial Group first reported a position in SNDX in Q2 2021 and held it in 9 quarters. The position peaked at $1.19M in Q4 2023. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • Principal Financial Group reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 14,167 Syndax Pharmaceuticals shares in Q3 2024, an estimated $291K.
  • Principal Financial Group first reported a position in Syndax Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • Principal Financial Group's Syndax Pharmaceuticals position peaked at $1.19M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.